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Sub-Saharan Africa is a region of high hepatitis B virus (HBV) 
prevalence, where >75% of individuals have evidence of HBV expo-
sure and 10% of people are chronically infected.[1] HBV is transmitted 
by parenteral exposure to infected blood or body fluids and from 
mother to child. Exposure to HBV at an early age increases the chance 
of persistent infection and is responsible for maintaining the cycle of 
infection in regions of high endemicity. Prevalence studies conducted 
in South Africa (SA) before the introduction of infant immunisation 
suggested that peak acquisition of HBV mainly occurred in children 
between 1 and 5 years of age and that mother-to-child transmission 
(MTCT) was uncommon.[2-4] Accordingly, when the HBV vaccine 
was added to the infant immunisation schedule in the 1990s, it was 
given at 6, 10 and 14 weeks of age. Notably, a birth dose of vaccine was 
omitted for logistical reasons. Since then there has been a dramatic 
reduction in acute HBV infections and associated disease in children, 
and carriage rates have also declined.[5-6] However, HBV infections in 
children still occur in SA, owing either to gaps in vaccine coverage or 
MTCT as a result of failed prophylaxis.[7] The high rate of maternal 
HIV and HBV co-infection in SA may be another factor increasing 
transmission risk.[8-10] Mechanisms of MTCT of HBV are similar to 
those for HIV and transmission may occur in utero, intrapartum or 
via breast-feeding. Women who are hepatitis e-antigen (HBeAg)-
positive with high HBV viral loads (VLs) are more likely to transmit 
to their infants. Breakthrough infections occur in ~1 - 9% of this 
group, despite prophylaxis.[11] Though less common, HBeAg-negative 
women can also transmit HBV infection and this can have severe 
consequences for their infants.[12]
The current HBV prophylaxis in SA falls woefully short of 
current international recommendations, namely that all infants 
should receive a birth dose of HBV vaccine (as recommended by the 
World Health Organization[13]), pregnant women should be screened 
for hepatitis B surface antigen (HBsAg), and HBV VL should be 
performed on positive patients. Lastly, mothers with HBV VLs 
>200  000 IU/mL (American Association for the Study of the Liver 
and European Association for the Study of the Liver) or >6 log IU/mL 
(Asian Pacific Association for the Study of the Liver) should receive 
antiviral prophylaxis with lamivudine, telbivudine or tenofovir in the 
second and third trimesters of pregnancy.[14] 
Case report
A 10-week-old male infant was admitted to Red Cross War Memorial 
Children’s Hospital in Cape Town, SA, on 25 November 2016 with 
fever and poor feeding of 3 days’ duration. He was receiving breast 
and formula milk feeds. He had received an intramuscular dose 
of a combination vaccine (HBV, Haemophilus influenzae type B, 
diphtheria, tetanus, acellular pertussis and inactivated polio) 4 days 
prior to admission. There was no history of diarrhoea, vomiting, 
cough, seizures, jaundice or recent travel. His mother was from the 
Democratic Republic of Congo (DRC). She had arrived in Cape Town 
while pregnant and had a normal vaginal delivery in Cape Town at 
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39 weeks’ gestation. The baby’s birth weight was 3 660 g, he had good 
Apgar scores, birth RPR for syphilis was negative, his immunisation 
status was up to date, and there was no history of contact with 
individuals with tuberculosis. He had not received any medication 
prior to presentation.
At presentation, his temperature was 38.8oC, he was active 
and not jaundiced, the findings on abdominal examination were 
normal, and there was no clinically evident focus of infection. 
Dipstick examination of the urine was negative, cerebrospinal fluid 
examination was not suggestive of meningitis, and a chest radiograph 
showed patchy infiltrates in the left lung field. Because neonatal 
sepsis was suspected he was commenced on intravenous cefotaxime 
and ampicillin pending the results of blood culture, which ultimately 
demonstrated no microbial growth.
On the 4th day of admission, marked jaundice was observed 
and the results of liver function tests and a coagulation profile 
were markedly deranged: total bilirubin (TB) 170 mmol/L 
(normal 5 - 21 mmol/L), conjugated bilirubin (CB) 98 mmol/L 
(normal 0 - 6  mmol/L), alanine aminotransferase (ALT) 1 880 
U/L (normal 4 - 35 U/L), aspartate aminotransferase (AST) 
3 424  U/L (normal 0 - 65  U/L), alkaline phosphatase (ALP) 
1 481 U/L (normal 82 - 383  U/L), gamma-glutamyl transpeptidase 
(GGT) 145 U/L (normal 12 - 122 U/L), lactate dehydrogenase 
(LDH) 626 U/L (normal 180 - 430 U/L), ammonia 105 mmol/L 
(normal 40 - 80  mmol/L), international normalised ratio (INR) 
8.7 (normal 2.0 - 3.0), pro thrombin time (PT) 115.6 seconds 
(control 14.7 seconds), activated partial thromboplastin time (PTT) 
119.3  seconds (control 30.0 - 40.0 seconds), fibrinogen 0.9 g/L 
(normal 2.0 - 4.0 g/L) and factor V 7.5% (normal 48 - 132%). He 
had microcytic anaemia, a sickle test was normal, and his C-reactive 
protein (CRP) level was 21 mg/dL (normal <10 mg/dL).
Further laboratory results were as follows: negative hepatitis A 
immunoglobulin M (IgM), low-positive HBsAg (signal close to the 
cut-off for the assay), positive hepatitis B surface antibody (anti-
HBs) of 80.7 mIU/mL and negative hepatitis B core IgM. Hepatitis C 
antibody, hepatitis E IgM, herpes simplex virus 1 and 2 polymerase 
chain reaction (PCR), HIV DNA PCR, parvovirus B19 PCR, rubella 
IgM and Treponema pallidum antibody tests were negative. The 
cytomegalovirus VL was 730 IU/mL, the Epstein-Barr virus VL was 
lower than the detectable level, the thyroid-stimulating hormone 
level was 0.86 mIU/L (normal 0.72 - 11.0 mIU/L) and the thyroxine 
level was 21.2 pmol/L (normal 11.5 - 28.3 pmol/L). Galactosaemia 
and MPV17-related hepatocerebral mitochondrial DNA depletion 
syndrome were considered, but the common c.404C >T (p.5135L) 
and c.C106T (P.Q36X) mutations in the galactose-1-phosphate 
uridyltransferase (GALT) and MPV17 genes, respectively, were not 
detected. An abdominal ultrasound scan revealed a non-enlarged 
liver with coarse echotexture. The mother tested positive for HBsAg 
and hepatitis B e antibody (anti-HBe), but was HBeAg-negative. Her 
HBV VL was detectable at 760 IU/mL.
The clinical manifestations together with the laboratory findings 
suggested a diagnosis of fulminant hepatic failure secondary to 
vertical HBV infection. Treatment included vitamin K, oral lactulose 
and N-acetylcysteine. The infant received lamivudine and his 
antibiotics were changed to piperacillin/tazobactam and amikacin. 
He remained critically ill, requiring several platelet, cryoprecipitate 
and fresh frozen plasma infusions, and continued to deteriorate, 
becoming hypoglycaemic on day 10 of admission.
Table 1 shows evolution of the HBV markers. Repeat liver function 
tests and a repeat coagulation profile on day 15 of admission showed 
persistent derangements, i.e. TB 369 mmol/L, CB 93 mmol/L, ALT 
51 U/L, AST 55 U/L, ALP 3 227 U/L, GGT 32 U/L, LD 436 U/L, INR 
7.54, PT 86.3 seconds (control 12.6 seconds), PTT 109.8 seconds 
(control 29.5 seconds) and fibrinogen 0.7 g/L (normal 2.0 - 4.0 g/L). 
The infant remained critically ill, his liver transaminases continued 
to decline, the coagulopathy persisted, the jaundice worsened, and 
he continued to experience hypoglycaemic spells. He subsequently 
developed melaena and grade II encephalopathy. He continued to 
deteriorate and died on day 45 of admission.
Genetic analysis of HBV from mother and infant
Total nucleic acid was extracted from serum samples of mother and 
infant using the MagNA Pure LC automated extraction method as 
per the manufacturer’s instructions (Roche Diagnostics GmbH, 
Germany). For HBV genotype assignment, a semi-nested PCR was 
used to amplify a region of the surface and overlapping polymerase 
(S/pol) gene: primers P6F and P2R[15] in the first round and P7F[16] 
and P2R in the second. The PCR protocol from Smuts et al.[17] was 
followed with minor modifications.
The basal core promoter (BCP), pre-core/core region (PC) was 
amplified using a nested PCR protocol.[18] The entire surface antigen 
gene (preS1, preS2 and S) was amplified using primers and protocol 
from Chook et al.[19]
Bidirectional Sanger sequencing of the S/pol, BCP/PC and 
S amplicons was performed using the BigDye terminator cycle 
sequencing kit (Applied Biosystems, USA). The HBV genotype 
was determined using the web-based geno2pheno program (http://
www.geno2pheno.org/index.php).
To determine the heterogeneity of the BCP/PC and S genes, 
amplicons from both mother and infant were cloned into a 
pGEM-T vector according to the manufacturer’s instructions 
(Promega Corp., USA). Multiple clones were subjected to Sanger 
sequencing and aligned using BioEdit version 7.2.6.1 (Softpedia, 
Romania).
Table 1. Plasma markers of HBV infection in mother and infant
HBV marker Mother Infant, day 4 of admission Infant, day 17 of admission
HBsAg Positive Low positive Negative
Anti-HBs (mIU/mL) Negative 80 126
HB core IgM Negative Negative Low positive (1.21 S/CO)
HB e antigen Negative ND* ND*
Anti-HBe Positive ND ND
HBV VL (IU/mL) 760 465 209
Hepatitis D PCR ND Negative ND
HBV = hepatitis B virus; HBsAg = hepatitis B surface antigen; anti-HBs = hepatitis B surface antibody; IgM = immunoglobulin M; anti-HBe = hepatitis B e antibody; S/CO = signal/cut-off;  
ND = not done; VL = viral load; PCR = polymerase chain reaction.
*Insufficient sample available to perform e-antigen testing. Sequence analysis of infant’s virus indicated the e-minus phenotype.
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Discussion
We present this case because it highlights 
the need to improve HBV prophylaxis to 
infected mothers and their infants. The 
case is unusual because the mother was 
anti-HBe-positive and had a low VL, only 
760  IU/mL, but still transmitted infection 
to her infant. Also, the infant developed a 
fulminant infection that led to his death. The 
commonest scenario associated with MTCT 
of HBV is when the mother is HBeAg-posi-
tive and has a high HBV VL (>6 log IU/mL). 
This was previously reported to be relatively 
uncommon in Africa and accounted for the 
decision to omit a birth dose of HBV vaccine 
from the infant immunisation schedule in 
SA. However, more recent studies have 
found that between 18% and 37% of 
HBV-positive pregnant women in SA are 
HBeAg-positive. [9,10,20] Many HBV-positive 
individuals are co-infected with HIV, and 
this could influence the HBeAg status of 
infected individuals.
Was this MTCT?
Genetic analysis of the virus in mother 
and infant samples showed that both were 
infected with HBV genotype E. The mother 
was from the DRC, and genotype E is a 
predominant HBV genotype found in that 
country.[1] Sequence analysis of the BCP/
PC genomic region and the preS1, preS2 
and S open reading frames (ORFs) of HBV 
revealed that the mother’s and infant’s 
viruses had multiple signatures in common, 
providing evidence that their infections were 
indeed epidemiologically linked. Common 
motifs included a near-identical deletion in 
the preS2 region (position 399 - 420 in the 
mother and position 402 - 420 in the infant), 
a 3-nucleotide insertion at position 598 - 600 
in the small S ORF, and multiple single-
nucleotide polymorphisms (Fig. 1, A and B).
The HBeAg-negative phenotype  
and its significance
HBV infection in infants and young children 
is usually associated with subclinical infec-
tion. Liver damage/hepatitis in HBV infec-
tion is immune mediated (due to cell-
mediated immune attack on HBV-infected 
liver cells). The milder clinical illness in 
the very young has been attributed to the 
tolerising effect of HBeAg. This protein is 
a potent immune modulator and immune 
evasion molecule, acting at multiple levels to 
induce immune tolerance: it blocks cellular 
responses to type 1 and 3 interferons,[21] 
interferes with toll-like receptor signalling 
and induces the expression of PD-1 (an 
exhaustion marker) on CD8+ cells, com-
promising their antiviral activity.[22] The 
effect of this is to attenuate the antiviral 
immune response (and severity of clinical 
hepatitis) and enable the virus to establish 
persistent infection in the host.
Both the mother’s and the infant’s virus 
had the common G1896A mutation in the 
BCP/PC region. This mutation is frequently 
selected for during the immune-active phase 
of chronic HBV infection and probably 
became the predominant species in the 
mother’s blood years before. This mutation 
introduces a stop codon that truncates the 
HBeAg protein at the level of translation. 
In addition, the mother’s virus had further 
mutations in the BCP region (1762T, 1764A), 
known to reduce the synthesis of the pre-C 
mRNA transcript from which the HBeAg is 
synthesised. Transmission of HBV lacking 
functional HBeAg prevents the establishment 
of chronic infection but predisposes to more 
severe clinical hepatitis (due to the vigorous 
immune attack on infected liver cells). The 
fact that HBsAg was negative in the second 
blood sample from the infant is evidence 
that he was indeed clearing the infection. 
In a study of infants infected with HBV 
through MTCT, HBeAg-negative status in 
mothers was more likely to be associated with 
fulminant hepatitis in their infants, while 
infants of HBeAg-positive mothers were 
more likely to have mild hepatitis followed by 
chronic infection.[12]
When did transmission happen?
MTCT of HBV can occur in utero, intra-
partum or after birth (in breast-fed 
infants). As for HIV, the greatest risk of 
HBV transmission is during birth and this 
is when transmission probably occurred 
in this case. [23] The infant received his 
first dose of HBV vaccine at 6 weeks of 
age and the second, just days before the 
clinical presentation, too late to prevent 
transmission. Viruses from breakthrough 
infections that occur in infants who have 
received HBV immunoglobulin or vaccine 
at birth frequently have mutations that alter 
the antigenicity of the major neutralising 
domain of the viral HBsAg, in the so-called 
‘a’ determinant. Most common is a glycine-
to-arginine change at amino acid position 
145, first described by Carman et al.[24] This 
mutation arises because the presence of 
neutralising antibody early on selects for 
viral variants with altered HBsAg protein 
that is not neutralised by the antibody. No 
changes were present in this region in either 
BCP/PC          A1762T        G1764A         C1766T       T1768A       KOZAC                                         T1858C        G1862T         G1896A        G1899A
PC start 
codon
1814 - 16
Mother                 T                    A                     C                    A               GCAC                 ATG                      T                     G                     A                      G
Infant                   A                    G                     G                    A               GCAC                ATG                      T                     G                      A                     A
preS1                             preS2 open reading frame          s ag start                 s ag open reading frame          'a' determinant
preS2
start
Mother                  -                 ATG                                                                           ATG                                                                                      Wild type
Infant                     -                 ATC                                                                           ATG                                                                                      Wild type
21nt del 399 - 420 
(in frame 7 aa deletion)
3nt insertion at position 
598 - 600 (aa = L, 200)
18nt del 402 - 420 
(in frame 6 aa deletion)
3nt insertion at position
598 - 600 (aa = L, 200)
A
B
BCP Pre-C ORF
Fig. 1. Genetic features of HBV present in mother and infant blood. (A) Sequence analysis of the BCP and 
PC region revealed that immune escape mutations A1762T and G1764A were present in the mother’s 
virus, but absent from the infant’s virus. Both contained the G1896A mutation, which truncates the 
HBeAg protein and confers the e-minus phenotype. (B) In the preS/S genes, the preS2 start codon was 
mutated in the infant’s virus, but intact in the mother’s. Both had large deletions in the preS2 gene, and 
there was a 21nt deletion from 399 to 420 in the mother’s virus and an 18nt deletion from 402 to 420 in 
the infant’s virus. A 3nt insertion was present in the small S ORF in both the mother’s and the infant’s 
virus. The ‘a’ determinant was unchanged. (BCP = basal core promoter; Pre-C = pre-core; ORF = open 
reading frame; PC = pre-core/core; s Ag = surface antigen; nt = nucleotide; aa = amino acid. Mutations 
and deletions in the HBV genome in mother and infant blood are indicated in red.)
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the mother’s or the infant’s virus, suggesting that the infection was 
already well established before the first dose of vaccine.
Conclusion
While this is a rare complication of HBV infection, it highlights the 
fact that vertical infections in infants do occur in SA despite current 
prophylaxis. Most transmissions from HBeAg-positive mothers 
are probably missed, as the infants do not present with a typical 
clinical illness, and it is the rare fulminant presentations that draw 
attention. Current HBV prophylaxis in SA is out of step with current 
guidelines.[14] Introduction of a birth dose of vaccine alone would 
improve efficacy, but given the prevalence of HBV infection among 
local pregnant women, we consider that prenatal screening is needed. 
Screening could be done at booking using a rapid test for HBsAg. The 
most cost-effective approach would be for women who test positive 
to receive tenofovir prophylaxis in the second to third trimesters. 
A small field study has already demonstrated the feasibility of this 
approach in the Western Cape Province.[25] Also, the safety and 
acceptability of this drug has already been established for HIV-
infected pregnant women.
Teaching points
• Mother-to-child HBV transmission may occur even when the 
maternal VL is low (<3 log IU/mL).
• Fulminant hepatitis in this infant was due to transmission of an 
HBV strain unable to express the e-antigen.
• This case provides evidence of failure of the current infant HBV 
prophylaxis programme in SA.
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